Prostate-specific membrane antigen (PSMA) is overexpressed in nearly all primary prostate cancer [1], and PSMA expression further increases in de-differentiated, metastatic, or hormone-refractory disease [2, 3]. This evidence concerns the gene FOLH1 and prostate carcinoma.